miR21对宫颈癌Hela细胞及顺铂耐药Hela/DDP细胞顺铂敏感性的影响

摘要
图/表
参考文献(20)
相关文章 (1)

全文: PDF (785 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨miR21基因表达水平对宫颈癌Hela细胞及其顺铂耐药Hela/DDP细胞顺铂敏感性的影响。方法利用riboFECTTM CP转染试剂分别将成熟miR21 mimic、inhibitor及其阴性对照试剂NC转染至Hela与Hela/DDP细胞，并将Hela细胞分为mimic组、阴性对照（NC）组和空白对照（Blank）组，将Hela/DDP细胞分为inhibitor组、阴性对照NC组和空白对照（Blank）组。Real-time PCR检测各组细胞中miR21的表达水平；MTT检测各组细胞对顺铂的半数抑制率浓度（IC50值）。结果 ①Real-time PCR检测miR21在Hela/DDP中高表达，是Hela的（5.452±0.074）倍（P < 0.01）；转染mimic后，Hela中miR21表达高于明显NC组及Blank组（P < 0.01），NC组与Blank组相比，差异无统计学意义（P ＞ 0.05）；转染inhibitor后，Hela/DDP中miR21表达明显低于NC组及Blank组（P < 0.01），NC组与Blank组相比，差异无统计学意义（P ＞ 0.05）。②MTT结果显示，转染mimic后Hela细胞对顺铂敏感性下降，与NC组及Blank组相比，差异有统计学意义（P < 0.05），NC组与Blank组相比，差异无统计学意义（P ＞ 0.05）；转染inhibitor后Hela/DDP细胞对顺铂敏感性增加，与NC组及Blank组相比，差异有统计学意义（P < 0.05），NC组与Blank组相比，差异无统计学意义（P ＞ 0.05）。结论 ①miR21在Hela/DDP中高表达，在Hela中低表达。②上调miR21在Hela中的表达能明显降低其对顺铂的敏感性，下调miR21在Hela/DDP中的表达能明显增加其对顺铂的敏感性。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	岳晓雪1 苗劲蔚2 路攀1

关键词 ：宫颈癌细胞, 顺铂耐药细胞, miR21, 顺铂, 化疗敏感性

Abstract：Objective To detect the influence of miR21 gene expression on the sensitivity of cervical cancer Hela cells and cisplatin-resistant Hela/DDP cells to cisplatin. Methods Mature miR21 mimic, inhibitor and negative control (NC) miRNA were transfected into Hela and Hela/DDP cells by riboFECTTM CP. Hela cells were divided into mimic group, NC group and Blank group and Hela/DDP were divided into inhibitor group, NC group and Blank group. Real-time PCR was used to measure the expression of miR21 in each group. MTT was used to detect the half inhibitory concentration (IC50) of cisplatin. Results ①Real-time PCR results showed that the expression of miR21 was an average of (5.452±0.074) fold higher in Hela/DDP than in Hela (P < 0.01). The expression of miR21 in mimic group was obviously higher than those in NC and Blank groups (P < 0.01). The expression of miR21 in inhibitor group was significantly lower than those in NC and Blank groups (P < 0.01). There was no statistical difference between NC group and Blank group in Hela and Hela/DDP cells (P ＞ 0.05). ②MTT results showed that the sensitivity of Hela to cisplat in decreased after mimic transfection while the Hela/DDP increased after transfected with inhibitor (P < 0.05). There was no significant difference between NC group and Blank group (P ＞ 0.05). Conclusion ①The expression of miR21 is upregulated in Hela/DDP cells, while it wis down regulated in Hela cells. ②Over expression of miR21 in Hela can reduce its sensitivity to cisplatin obviously. Inhibition of miR21 in Hela/DDP can significantly increase its sensitivity tocisplatin.

Key words： Hela Hela/DDP miR21 Cisplatin Cheosensitivity

基金资助:首都医科大学基础-临床科研合作基金项目（2016-JL-PT-Y02）；
北京市科学技术委员会重点项目（D13110000 5313009）。

通讯作者: 苗劲蔚（1968.6-），女，博士，主任医师；研究方向：妇科肿瘤。

作者简介: 岳晓雪（1993.8-），女，首都医科大学2016级妇产科学专业在读硕士研究生；研究方向：妇科肿瘤微创临床、基础研究。

引用本文:

岳晓雪1 苗劲蔚2 路攀1 . miR21对宫颈癌Hela细胞及顺铂耐药Hela/DDP细胞顺铂敏感性的影响[J]. 中国医药导报, 2017, 14(36): 25-28.
YUE Xiaoxue1 MIAO Jinwei2 LU Pan1. Effect of miR21 on cisplatin chemosensitivity of cervical cancer Hela cells and cisplatin-resistant Hela/DDP cells. 中国医药导报, 2017, 14(36): 25-28.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2017/V14/I36/25

[1] Siegel R，Naishadham D，Jemal A. Cancer statistics，2012 [J]. CA Cancer J Clin，2013，63（1）：11-30.
[2] 许卫东，何合良，赵一虹，等.中晚期宫颈癌顺铂同步放化疗与单纯放疗治疗疗效比较[J].中华肿瘤防治杂志，2017，11：5456.
[3] Liu B，Pan CF，Ma T，et al. Long non-coding RNA AK0 01796 contributes to cisplatin resistance of non small cell lung cancer [J]. Mol Med Rep，2017，16（4）：4107-4112.
[4] Jang HS，Woo SR，Song KH，et al. API5 induces cisplatin resistance through FGFR signaling in human cancer cells [J]. Exp Mol Med，2017，49（9）：e374.
[5] Donzelli S，Mori F，Biagioni F，et al. MicroRNAs：short non-coding players in cancer chemoresistance [J]. Mol Cell Ther，2014，2（1）：16.
[6] Geretto M，Pulliero A，Rosano C，et al. Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators [J]. Am J Cancer Res，2017，7（6）：1350.
[7] Zheng P，Li C，Yuan X，et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells [J]. J Exp Clin Cancer Res，2017，36（1）：53.
[8] Rui M，Qu Y，Gao T，et al. Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells [J]. Int J Nanomedicine，2016，12：217-237.
[9] Ziyan W，Yang L. MicroRNA-21 regulates the sensitivity to cisplatin in a human osteosarcoma cell line [J]. Ir J Med Sci，2014，185（1）：1-7.
[10] Au Yeung CL，Co NN，Tsuruga T，et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1 [J]. Nat Commun，2016，7：11 150.
[11] Li X，Qian X，Li X，et al. MicroRNA-21 regulates the proliferation and apoptosis of cervical cancer cells via tumor necrosis factor-α [J]. Mol Med Rep，2017，16（4）：4659-4663.
[12] Abue M，Yokoyama M，Shibuya R，et al. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer [J]. Int J Oncol，2015，46（2）：539-547.
[13] Leite KRM，Reis ST，Viana N，et al. Controlling RECK miR21 promotes tumor cell invasion and is related to biochemical recurrence in prostate cancer [J]. J Cancer，2015，6（3）：292-301.
[14] Danilova OV，Paiva C，Kaur P，et al. MIR21 is differentially expressed in the lymphoid tissue and modulated by stromal signalling in chronic lymphocytic leukaemia [J]. Br J Haematol，2015，170（2）：272.
[15] Zheng Z，Xu PP，Wang L，et al. MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells [J]. Exp Clin Cancer Res，2017，36（1）：82.
[16] Asaga S，Kuo C，Nguyen T，et al. Direct serum assay for MicroRNA-21 Concentrations in early and advanced breast cancer [J]. Clin Chem，2011，57（1）：84.
[17] Wang ZX，Lu BB，Wang H，et al. MicroRNA-21modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN [J]. Arch Med Res，2011，42（4）：281-290.
[18] Li Y，Li W，Yang Y，et al. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme [J]. Brain Res，2009，1286（2）：13-18.
[19] Chan JK，Blansit K，Kiet T，et al. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer [J]. Gynecol Oncol，2014，132（3）：739-744.
[20] Shen H，Zhu F，Liu J，et al. Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer [J]. PLoS One，2014，9（7）：e103 305.